Profound Medical Corp.

Name: Profound Medical Corp. standardized financial statements, quarterly
Creator: Listed

PROFNasdaqCIK 1628808HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$2.5m, Q2 FY2026

Operating income−$11.1m, Q2 FY2026

Net income−$9.5m, Q2 FY2026

Profound Medical Corp., income statement, quarterly
Line item	Unit	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	1.2	2.0	2.5	4.0	2.3	2.0	5.1	6.7	5.3	2.5
Cost of revenue	$m	0.6	0.8	1.0	1.2	0.8	0.6	1.4	2.0	1.5	0.5
Gross profit	$m	0.9	1.4	1.8	3.0	1.9	1.6	3.9	4.0	3.8	1.9
Research and development	$m	3.9	4.2	4.2	4.6	4.8	6.1	5.4	4.3	5.3	5.7
Selling, general and administrative	$m	4.8	5.1	6.6	6.7	8.2	9.3	7.4	7.1	6.6	7.4
Operating income	$m	(7.9)	(7.8)	(9.0)	(8.3)	(11.2)	(13.8)	(8.9)	(7.4)	(8.0)	(11.1)
Income tax	$m	0.0	0.0	0.2	(0.2)	0.0	0.1	0.1	0.0	0.0	0.1
Net income	$m	(6.6)	(6.9)	(9.4)	(4.9)	(10.7)	(15.7)	(8.0)	(8.2)	(7.1)	(9.5)
Diluted EPS	$ per share	0.27	0.28	0.38	not reported	0.36	(0.52)	0.26	not reported	0.19	(0.26)
Basic EPS	$ per share	0.27	0.28	0.38	not reported	0.36	(0.52)	0.26	not reported	0.19	(0.26)

Balance sheet

Cash and equivalents$38.3m, Q2 FY2026

Long-term debt$4.5m, Q2 FY2026

Shareholders' equity$49.8m, Q2 FY2026

Profound Medical Corp., balance sheet, quarterly
Line item	Unit	FY20222022-12-31	FY20232023-12-31	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	46.5	26.2	not reported	not reported	not reported	54.9	46.4	35.2	24.8	59.7	50.3	38.3
Current assets	$m	62.0	41.9	not reported	not reported	not reported	69.1	59.9	48.8	41.5	76.1	69.5	58.9
Total assets	$m	64.4	44.0	not reported	not reported	not reported	70.2	60.9	49.7	42.3	77.5	73.5	62.4
Current liabilities	$m	4.2	6.4	not reported	not reported	not reported	6.6	5.3	5.7	9.9	6.1	10.6	9.1
Total liabilities	$m	12.4	12.7	not reported	not reported	not reported	9.8	10.1	10.4	10.2	11.0	14.0	12.6
Long-term debt	$m	7.2	5.0	not reported	not reported	not reported	2.9	4.5	4.5	4.5	4.5	4.5	4.5
Current portion of debt	$m	not reported	2.1	not reported	not reported	not reported	1.7	not reported	not reported	4.5	not reported	4.5	4.5
Shareholders' equity	$m	52.6	31.2	45.5	38.9	30.7	60.4	50.8	39.3	32.1	66.4	59.4	49.8

Cash flow

Operating cash flow−$11.3m, Q2 FY2026

Profound Medical Corp., cash flow, quarterly
Line item	Unit	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(4.5)	(6.2)	(6.8)	(5.9)	(8.3)	(13.7)	(9.6)	(6.6)	(8.6)	(11.3)

Diluted shares (weighted)36.35m, Q2 FY2026

Profound Medical Corp., shares, quarterly
Line item	Unit	period not labelled2024-03-31	period not labelled2024-06-30	period not labelled2024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	24.3	24.4	24.5	30.0	30.1	30.1	36.3	36.4

Shares outstanding: 36.53m at Aug 6, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.